Phenobarbitone in Rh hemolytic disease of the newborn: A randomized double-blinded placebo-controlled trial

Venkatnarayan, Kannan ; Sankar, Mari Jeeva ; Agarwal, Ramesh ; Paul, Vinod K. ; Deorari, Ashok K. (2013) Phenobarbitone in Rh hemolytic disease of the newborn: A randomized double-blinded placebo-controlled trial Journal of Tropical Pediatrics, 59 (5). pp. 380-386. ISSN 0142-6338

Full text not available from this repository.

Official URL: https://academic.oup.com/tropej/article/59/5/380/1...

Related URL: http://dx.doi.org/10.1093/tropej/fmt032

Abstract

Objective: To evaluate the efficacy of prophylactic oral phenobarbitone (PB) in neonates with Rh hemolytic disease of the newborn. Study Design: In this double-blind randomized trial conducted in a tertiary care unit, we randomly allocated neonates with Rh hemolytic disease of the newborn born at or after 32 weeks’ gestation to PB (10 mg/kg/day on day 1 followed by 5 mg/kg/day on days 2–5) (n = 23) or oral glucose (n = 21). The primary outcome was the duration of phototherapy. Results: Baseline variables were comparable. There was no difference in the median duration of phototherapy [54 (range: 0–180) vs. 35 h (0–127); p = 0.39] and in the incidences of failure of phototherapy or significant rebounds of serum bilirubin. However, the proportion of infants with cholestasis was significantly lower in the PB group (0 vs. 19%; p = 0.04). Conclusions: PB does not reduce duration of phototherapy or its episodes. Its potential to reduce cholestasis needs validation in larger studies.

Item Type:Article
Source:Copyright of this article belongs to Oxford University Press.
Keywords:Rh Hemolytic Disease of the Newborn (Rh-HDN; Phenobarbitone; Phototherapy
ID Code:104371
Deposited On:08 Dec 2017 09:55
Last Modified:08 Dec 2017 09:55

Repository Staff Only: item control page